SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 5, 2004
REPLIGEN CORPORATION
(Exact name of registration as specified in charter)
Delaware 0-14656 04-2729386
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (781) 250-0111
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 5. Other Events.
On January 5, 2004, Repligen Corporation announced that its phase 3 study
of secretin for autism failed to meet the study's dual primary endpoints and
that development of secretin for schizophrenia would continue. The full text of
the press release issued in connection with the announcement is attached as
Exhibit 99.1 to this Current Report on Form 8-K.
Item 7. Financial Statement and Exhibits.
(c) Exhibit No. Exhibit
----------- -------
99.1 Press Release, dated January 5, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
REPLIGEN CORPORATION
Dated: January 5, 2004 By: /s/ Walter C. Herlihy
---------------------------------
Walter C. Herlihy
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Exhibit
----------- -------
99.1 Press Release, dated January 5, 2004